Inmune Bio, Inc. financial data

Symbol
INMB on Nasdaq
Location
225 Ne Mizner Blvd, Suite 640, Boca Raton, FL
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 7, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 308 % +33.2%
Debt-to-equity 29.8 % -38%
Return On Equity -46.3 %
Return On Assets -132 % -91.9%
Operating Margin -26.2K % -152%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 26.6M shares +34.4%
Common Stock, Shares, Outstanding 26.6M shares +34.9%
Entity Public Float 135M USD +27.4%
Common Stock, Value, Issued 27K USD +35%
Weighted Average Number of Shares Outstanding, Basic 23.3M shares +20.7%
Weighted Average Number of Shares Outstanding, Diluted 23.3M shares +20.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 50K USD +257%
Research and Development Expense 30.9M USD +11.3%
General and Administrative Expense 8.9M USD -12.2%
Operating Income (Loss) -56.2M USD -48.8%
Nonoperating Income (Expense) 113K USD -5.04%
Net Income (Loss) Attributable to Parent -55.5M USD -47.1%
Earnings Per Share, Basic -2 USD/shares -20.4%
Earnings Per Share, Diluted -2 USD/shares -20.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 33.4M USD +7.42%
Accounts Receivable, after Allowance for Credit Loss, Current 1.61M USD -48.9%
Assets, Current 36M USD +1.52%
Property, Plant and Equipment, Net 706K USD
Operating Lease, Right-of-Use Asset 374K USD +3.03%
Intangible Assets, Net (Excluding Goodwill) 16.5M USD 0%
Other Assets, Noncurrent 570K USD +604%
Assets 37.7M USD -28.2%
Liabilities, Current 8.59M USD -43%
Operating Lease, Liability, Noncurrent 231K USD -28.3%
Liabilities 8.82M USD -42.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax -763K USD -7.01%
Retained Earnings (Accumulated Deficit) -197M USD -39.1%
Stockholders' Equity Attributable to Parent 28.9M USD -20.4%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 50.7M USD -27.6%
Liabilities and Equity 37.7M USD -28.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.82M USD +8.72%
Net Cash Provided by (Used in) Financing Activities 5.27M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 26.6M shares +34.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.59M USD +83.9%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 33.4M USD +7.42%
Interest Paid, Excluding Capitalized Interest, Operating Activities 302K USD -32.9%
Deferred Tax Assets, Valuation Allowance 25.7M USD +31%
Deferred Tax Assets, Gross 25.7M USD +31.1%
Operating Lease, Liability 451K USD -0.22%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -55.6M USD -47.2%
Lessee, Operating Lease, Liability, to be Paid 505K USD -5.61%
Operating Lease, Liability, Current 220K USD +69.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 91K USD -54%
Lessee, Operating Lease, Liability, to be Paid, Year One 278K USD +44.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 54K USD -34.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 51K USD -74.2%
Deferred Tax Assets, Operating Loss Carryforwards 8.69M USD +26.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 51K USD
Operating Lease, Payments 77K USD
Additional Paid in Capital 227M USD +26.9%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 545K USD
Share-based Payment Arrangement, Expense 1.53M USD -34.7%
Interest Expense 0 USD -100%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%